Europe Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, I

Europe Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)

The Europe carbapenem-based antibiotics market is expected to reach US$ 1,469.86 million by 2028 from US$ 1,128.37 million in 2021; it is estimated to grow at a CAGR of 3.8% from 2021 to 2028.

The market's growth is attributed to factors such as the rising prevalence of bacterial infections and increasing private and public partnerships of leading pharmaceutical players. However, the tedious and expensive process of developing antibiotics is expected to restrain the market's growth during the forecast period.

Antimicrobial resistance (AMR) has become a significant threat worldwide. Due to environmental factors such as exposure to antibiotics and spontaneous mutations, bacteria are becoming highly resistant to many antibiotics. Therefore, various strategies are designed to measure and control the spread of AMR. Several governments and healthcare authorities implement constructive plans to combat such critical situations. In 2017, the government of Germany announced the launch of the Global R&D Collaboration Hub to oppose AMR to focus on bridging gaps in the new developments. In January 2019, the UK government launched its strategy to deal with AMR. The UK's government has a 5-year national action plan to deal with antimicrobial resistance. Also, it has the vision to reduce AMR by 2040. The plan was developed across the governments, including Scotland, Wales, and Northern Ireland, and their agencies and administrations with the support of a range of stakeholders.

In April 2020, Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership (GARDP) announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam. It is a broad-spectrum beta-lactamase inhibitor that restores the activities of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA). However, it is an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam. Under the collaboration, GARDP and Venatorx look forward to developing cefepime-taniborbactam. The combination is under a phase 3 c UTI trial. Additionally, clinical trials in adults with multidrug-resistant infections and clinical development activities and trials to enable cefepime-taniborbactam for children, including newborns with severe bacterial infections, are being conducted. Such activities by public and private partnerships are projected to offer lucrative opportunities for the growth of the carbapenem-based antibiotics market during the forecast period.

Europe Carbapenem-Based Antibiotics Market Revenue and Forecast to 2028 (US$ million)

EUROPE CARBAPENEM-BASED ANTIBIOTICS MARKET SEGMENTATION

By Type

Meropenem Imipenem Doripenem Tebipenem Others By Indication

Bacterial Meningitis Acute Pelvic Infections Respiratory Tract Infections Intra-Abdominal Infections Urinary Tract Infections Others By Distribution Channel

Hospital Pharmacies Retail Pharmacies Online Pharmacies By Country

Italy France UK Germany Spain Rest of Europe Company Profiles

ACS Dobfar S.p.A Iterum Therapeutics plc Aurobindo Pharma Ltd Gland Pharma Limited Merck & Co., Inc. Sumitomo Dainippon Pharma Co., Ltd. Savior Lifetec Pfizer Inc. Spero Therapeutics

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe carbapenem-based antibiotics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe carbapenem-based antibiotics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.